Inquiry Basket
Loading ......
Creative Diagnostics offers an antibody production service using our proprietary mRNA-LNP platform. This service is an ideal option for quickly producing high-quality antibodies, particularly for membrane proteins, unstable epitopes, or difficult targets that require high conformational specificity. We combine our custom mRNA design, synthesis, and LNP encapsulation with our in-house immunization and screening capabilities to offer a fast and robust option for antibody generation. The mRNA-LNP platform enables in vivo expression of the target antigen for immunization, instead of traditional protein immunization. The sequences encoding the antigen of interest are engineered into optimized mRNA and encapsulated within lipid nanoparticles (LNPs) for delivery. The endogenous processes of mRNA translation and antigen presentation are used to elicit a high-affinity antibody response with our optimized LNP formulations.
NanoAssemblr™
Zetasizer Ultra
Synergy™ H1 Hybrid Reader
Our Antibody Services span the entire process of designing and generating high affinity, high specificity antibodies for applications in research, diagnostics and therapeutic antibody discovery. Our expertise in mRNA technologies and LNP delivery form the backbone of our customized immunization approaches, which allow us to tailor the best solution to the specific challenges of each target antigen. Our platform brings together optimized mRNA construct design, efficient LNP formulation and cutting-edge screening and validation strategies to ensure a consistent and reliable process for the generation of high-quality antibodies for ELISA, Western blot, immunohistochemistry, flow cytometry and biosensor applications. We are committed to providing you with reproducible antibodies with superior specificity. We provide:
In response to the growing need for rapid and precise antibody generation, we offer comprehensive mRNA-LNP-based Antibody Services. We adopt advanced mRNA synthesis and lipid nanoparticle (LNP) delivery platform technology to achieve in vivo expression of target proteins for immunization, even in cases where traditional methods are difficult to apply due to low immunogenicity, structural instability, high molecular weight, and other such properties. Our platform's service scope ranges from the optimal mRNA sequence design and efficient LNP formulation to customized immunization and animal observation procedures to achieve the desired antibody production and epitope coverage. This platform can be used for therapeutic antibody screening, biomarker validation and high sensitivity immunoassay development. Our robust quality control program and technical expertise ensure that all the antibodies produced on our platform are highly specific, stable and consistent between batches. Our core services include:
We provide validation services tailored to your application, including:
A comprehensive analysis report is included with every project.
Assess target antigen properties and define immunization goals.
Design mRNA and formulate lipid nanoparticles for efficient delivery.
Immunize animals with mRNA-LNPs and monitor antibody levels.
Identify high-affinity antibodies and verify their specificity.
Produce and purify antibodies; provide technical support.
BLI Sensorgram Showing High-Affinity Binding Kinetics of mRNA-LNP-Induced Monoclonal Antibody. Real-time binding curves were generated for different antibody concentrations (0.5–10 nM) using biolayer interferometry (BLI). The curves illustrate rapid association and slow dissociation rates, indicating high-affinity interaction with the target antigen. The estimated kon/koff values (kon ≈ 1.0 × 105 M-1s-1, koff ≈ 4.0 × 10-5 s-1) give a KD ≈ 0.4 nM, showing the antibodies isolated from this mRNA-LNP immunization platform to have strong binding.
Instead of injecting the actual protein, we deliver the instructions (mRNA) for the body to make the antigen itself. This means faster development, better mimicry of native protein structure, and stronger immune responses—especially for tricky targets like membrane proteins.
Pretty much! It's really nice for hard-to-express or unstable proteins, such as multi-pass membrane proteins or conformational epitopes. If we can encode the antigen, we can usually design an mRNA for it.
Typically around 8 to 12 weeks from mRNA design to antibody candidates, which is faster than conventional approaches. Some timelines vary depending on complexity and species.
Yes, mRNA-LNP immunization is well-tolerated in standard animal models like mice and rabbits. The LNPs are biodegradable, and no actual virus or pathogen is used.
Both! We can generate polyclonal antibodies from serum, or proceed with hybridoma or B cell cloning to develop monoclonal antibodies, depending on your project needs.
To use our mRNA-LNP-based antibody production services, please contact Creative Diagnostics, your expert immunology service provider. From research-scale mRNA-LNP-based antibody production to industrial scale-up, our team is ready to support your R&D innovation.
Loading ......
